Alberti A - Search Results

1

Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?

Alberti A. Alberti A. J Hepatol. 2004 Jun;40(6):1032-5. doi: 10.1016/j.jhep.2004.04.008. J Hepatol. 2004. PMID: 15158348 Review. No abstract available.

2

Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.

Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, Fagiuoli S, Realdon S, Alberti A. Gerotto M, et al. Among authors: alberti a. J Hepatol. 2006 Jan;44(1):83-7. doi: 10.1016/j.jhep.2005.08.016. Epub 2005 Sep 21. J Hepatol. 2006. PMID: 16271794

3

Therapy of acute hepatitis C.

Alberti A, Boccato S, Vario A, Benvegnù L. Alberti A, et al. Hepatology. 2002 Nov;36(5 Suppl 1):S195-200. doi: 10.1053/jhep.2002.36808. Hepatology. 2002. PMID: 12407594 Review.

4

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S; ECC Jury. Alberti A, et al. J Hepatol. 2005 May;42(5):615-24. doi: 10.1016/j.jhep.2005.03.003. J Hepatol. 2005. PMID: 15916745 Review. No abstract available.

5

Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels.

Alberti A. Alberti A. J Hepatol. 2005 Feb;42(2):266-74. doi: 10.1016/j.jhep.2004.12.004. J Hepatol. 2005. PMID: 15664254 Review. No abstract available.

6

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Romano A, et al. Among authors: alberti a. J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16. J Hepatol. 2018. PMID: 29551707

7

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group. Cammà C, et al. Among authors: alberti a. J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23. J Hepatol. 2013. PMID: 23707373

8

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Among authors: alberti a. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758

9

Management of hepatitis C.

Alberti A, Benvegnù L. Alberti A, et al. J Hepatol. 2003;38 Suppl 1:S104-18. doi: 10.1016/s0168-8278(03)00008-4. J Hepatol. 2003. PMID: 12591189 Review. No abstract available.

10

Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?

Alberti A. Alberti A. Hepatology. 2003 Jul;38(1):18-20. doi: 10.1053/jhep.2003.50280. Hepatology. 2003. PMID: 12829981 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,132 results

Search Page